Non-Toxin Antigens For Clostridioides Difficile Vaccine
AssigneesVanderbilt University, The United States Government as represented by the Department of Veterans Affairs
InventorsD. Borden LACY, Audrey THOMAS
Life of this patent
Estimating the term…
Abstract
Disclosed herein are C. difficile surface proteins that can serve as antigens in a vaccine to prevent C. difficile infection. While many trials have been focused on the use of the C. difficile toxins as antigens, the neutralization of toxins does not prevent colonization by the organism.
Claims12
A vaccine composition comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 C. difficile proteins (or immunogenic fragments thereof) selected from the group consisting of polysaccharide deacetylase, glucosaminidase domain-cont. protein, N-acetylmuramoyl-L-alanine amidase, C40 peptidase 1, C40 peptidase 2, FIgK (flagellar hook-associated protein), FlgD (flagellar basal body mod. protein), FIgG (flagellar basal body rod), FIgE (flagellar hook-basal body protein), DUF3794 domain-containing protein, S8 peptidase, N-acetylglucosaminidase, FliD (flagellar cap protein), NlpC/P60-family protein, Cell wall protein 12, and Cell wall protein 21, in a pharmaceutically acceptable carrier or excipient.
Dependencies are inferred from the claim text.